## SEC Form 5

	FORM	5	UNITED ST/	ATES SE	CURIT	IES .	AND EXC	HANC	GE CON	MISSION					
Check this box if no longer subject to					Washington, D.C. 20549							OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				AL STATI	CHANGE ERSHIP	CIAL	E	OMB Number: 3235-0362 Estimated average burden							
Form 3	3 Holdings Rep	orted.		-		-			hours per response:		1.0				
X Form 4	4 Transactions	Reported.	Fi				the Securities Ex stment Company								
1. Name and Address of Reporting Person <sup>*</sup> Patel Kinnari							or Trading Symbo ACEUTICA	(Check all appli Direct	cable) or · (give ti	10 ve title Ot		to Issuer 0% Owner ther (specify elow)			
(Last)(First)(Middle)C/O ROCKET PHARMACEUTICALS, INC.350 FIFTH AVENUE, SUITE 7530					ent for Issu 18	er's Fis	cal Year Ended (	1	Chief Operating Officer						
(Street) NEW Y	_ 4. If Amer	dment, Da	te of Or	iginal Filed (Mon	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person										
(City)	(S	tate)													
		Tat	ole I - Non-Deri	vative Sec	urities A	Acqui	red, Dispose	ed of, o	or Benefi	cially Owned	1				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da if any	Code	saction e (Instr.	4. Securities Acquired (A) or Dispose Of (D) (Instr. 3, 4 and 5)			d 5. Amount of Securities Beneficially Owned at end of		6. Ownersh Form: Di	ip Indi rect Ben	7. Nature of Indirect Beneficial	
				(Month/Day/\	'ear) 8)		Amount	(A) or (D)	Price	Usuer's Fiscal Year (Instr. 3 and 4)		(D) or Indirect ( (Instr. 4)		Ownership (Instr. 4)	
Common Stock			08/17/2018		1	<b>M</b> 4	55,869	A	\$1.2	.21 111,738		<sup>.)</sup> D			
Common	Stock									5,62	′5	I	By	spouse	
Common Stock										94,9	27	I		aptive hnology, C <sup>(2)</sup>	
			Table II - Deriva (e.g.,				ed, Disposed otions, conv								
1. Title of 2. 3. Transaction		3A. Deemed Execution Date	4. Transaction	5. Number		6. Date Exercisable and Expiration Date		Fitle and	8. Price of	8. Price of 9. Num		10. Ownership	11. Nature		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.21	08/17/2018		4M		55,869	(3)	04/18/2026	Common Stock	55,869	\$0	111,738 <sup>(4)</sup>	D		

## Explanation of Responses:

1. Reflects the total number of shares owned by the reporting person as of December 31, 2018 and as of the date hereof. The reporting person inadvertently failed to previously report the transaction reported herein. As a result, the shares that the reporting person held directly were understated by 55,869 shares in the reporting person's Form 4 report filed on December 21, 2018.

2. The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

3. This option represents a right to purchase a total of 167,607 shares of the Issuer's Common Stock 56,072 of which became fully vested and exercisable on April 18, 2017, with the remaining 111,535 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

4. Reflects the number of derivative securities beneficially owned following the transaction reported herein. The derivative securities that the reporting person beneficially owned were overstated by 55,869 derivative securities in the reporting person's Form 4 filed on December 21, 2018.

> /s/ Sara Turken, as attorney-in-04/26/2019 fact for Kinnari Patel

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.